Computer Aided Drug Design and Discovery of Novel Alzheimer’s Inhibitors

Host Organisation:	NovaMechanics Ltd
Partner Organisation(s):	PA 1: Erevnitiko Idryma P. L. Limited
Project Budget:	257.826,00 €
IDEK Funding:	199.988,40 €

The project aims at using advanced computational techniques to identify potent and superior compounds used for the treatment of Alzheimer’s disease (AD). Specifically, the project aims at identifying novel potent dual b secretase (BACE)/tau aggregation inhibitors, a class of disease modifying compounds, and therefore could be of significant interest for the AD treatment. Additionally, dual inhibitors fall in the multi target drug ligands (MTDL) which are recently thought to be superior than single target drugs for the treatment of complex diseases like AD. Towards this end they will develop the necessary computational and experimental methods and tools in order to identify and optimize potent BACE/tau aggregation inhibitors among compounds already synthesized and deposited in large databases